Workflow
Oncology and Immunology Treatments
icon
Search documents
Johnson & Johnson: Defensive Strength, Disciplined Growth, and Long-Term Value
Investing· 2026-01-22 06:43
Strong Q4 Results: Growth Accelerates as Profits Improve In the fourth quarter of 2025, Johnson & Johnson delivered a solid set of results that showed both steady growth and improving profitability. Revenue rose 9.1% from a year earlier to $24.56 billion, while net earnings jumped to $5.12 billion, reflecting stronger operating performance and easier comparisons. Earnings per share came in at $2.10 on a reported basis and $2.46 on an adjusted basis, highlighting healthy underlying momentum. Sales growth of ...